Therefore, it is possible that a new generation IFN-based agent, such as ropeginterferon alfa-2b, may provide promising new treatment options for patients with a metastatic cancer at a favorable benefit-risk balance. The gene discussed is IFNA1; the disease is metastatic malignant neoplasm.